Rapamycin impairs endothelial cell function in human internal thoracic arteries

European Journal of Medical Research

Volumn 20, Issue 1, 2015, Pages

  Reineke, David C ^a   Müller Schweinitzer, Else ^b,c   Winkler, Bernhard ^a,c   Kunz, Donatina ^b,c   Konerding, Moritz A ^d   Grussenmeyer, Thomas ^b,c   Carrel, Thierry P ^a   Eckstein, Friedrich S ^b,c   Grapow, Martin T R ^b,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Endothelial cells; eNOS; Internal thoracic artery; Mammalian target of rapamycin; Rapamycin

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN; SERINE; ANTIINFECTIVE AGENT; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BLOOD VESSEL FUNCTION; BREAST EPITHELIUM CELL; CELL FUNCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME RELEASE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCUBATION TIME; INTERNAL MAMMARY ARTERY; MAJOR CLINICAL STUDY; MALE; MORPHOLOGICAL TRAIT; SCANNING ELECTRON MICROSCOPY; TISSUE HOMOGENATE; VASODILATATION; WESTERN BLOTTING; CYTOLOGY; DRUG EFFECTS; GENETICS; MAMMARY ARTERY; METABOLISM; MIDDLE AGED; ULTRASTRUCTURE; VASCULAR ENDOTHELIUM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS; THORACIC ARTERIES; TOR SERINE-THREONINE KINASES;

EID: 84937035694     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/s40001-015-0150-4     Document Type: Article

References (24)

1. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471-84.
2. Moreno R, Fernández C, Hernández R, Alfonso F, Angiolillo DJ, Sabaté M, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005;45(6):954-9.
3. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48(12):2584-91.
4. Corbin F, Blaise GA, Parent M, Chen H, Daloze PM. Effect of rapamycin on rat aortic ring vasomotion. J Cardiovasc Pharmacol. 1994;24:813-7.
5. Milliard S, Silva A, Blaise G, Chen H, Xu D, Qi S, et al. Rapamycin's effect on vasomotion in the rat. Transplant Proc. 1998;30(4):1036-8.
6. Ramzy D, Rao V, Tumiati LC, Xu N, Miriuka S, Delgado D, et al. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine. Circulation. 2006;114(1 Suppl):I214-9.
7. Jeanmart H, Malo O, Carrier M, Nickner C, Desjardins N, Perrault LP. Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function. J Heart Lung Transplant. 2002;21:990-8.
8. Pendyala LK, Li J, Shinke T, Geva S, Yin X, Chen JP, et al. Endothelium-dependent vasomotor dysfunction in pig coronary arteries with Paclitaxel-eluting stents is associated with inflammation and oxidative stress. JACC Cardiovasc Interv. 2009;2(3):253-62.
9. Togni M, Ra¨ber L, Cocchia R, Wenaweser P, Cook S, Windecker S, et al. OM. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol. 2007;120(2):212-20.
10. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, et al. Hess OM. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol. 2005;46(2):231-6.
11. Copp J, Manning G, Hunter T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 2009;69:1821-7.
12. Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001;104(10):1188-93.
13. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science. 1991;251:283-7.
14. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J. 2006;27(2):166-70.
15. Mostafa AE, Richardt G, Abdel-Wahab M. Symptomatic abnormal vessel wall reaction after implantation of the first generation sirolimus-eluting stent: a case series. Cardiovasc Revasc Med. 2012;13:196-200.
16. Hegner B, Lange M, Kusch A, Essin K, Sezer O, Schulze-Lohoff E, et al. mTOR regulates vascular smooth muscle cell differentiation from human bone marrow-derived mesenchymal progenitors. Arterioscler Thromb Vasc Biol. 2009;29(2):232-8.
17. Zhao FH, Chen YD, Jin ZN, Lu SZ. Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents? Med Hypotheses. 2008;70:512-4.
18. Chen TG, Chen JZ, Wang XX. Effects of rapamycin on number activity and eNOS of endothelial progenitor cells from peripheral blood. Cell Prolif. 2006;39:117-25.
19. Barilli A, Visigalli R, Sala R, Gazzola GC, Parolari A, Tremoli E, et al. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res. 2008;78(3):563-71.
20. Dormond O, Madsen JC, Briscoe DM. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells. J Biol Chem. 2007;282:23679-86.
21. Contreras AG, Dormond O, Edelbauer M, Calzadilla K, Hoerning A, Pal S, et al. mTOR-understanding the clinical effects. Transplant Proc. 2008;40:9-12.
22. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;10:601-5.
23. Fisslthaler B, Dimmeler S, Hermann C, Busse R, Fleming I. Phosphorylation and activation of the endothelial nitric oxide synthase by fluid shear stress. Act Physiol Scand. 2000;168:81-8.
24. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res. 2002;28:1243-50.